Oct 8 (Reuters) - Transcode Therapeutics Inc ( RNAZ ):

* TRANSCODE THERAPEUTICS ( RNAZ ) ANNOUNCES THE ACQUISITION OF

POLYNOMA AND A $25 MILLION STRATEGIC FINANCING BY A SUBSIDIARY

OF CK LIFE SCIENCES TO FORM A FIRST-IN-CLASS UNIQUE

IMMUNO-ONCOLOGY AND METASTATIC PREVENTION ONCOLOGY COMPANY

* TRANSCODE THERAPEUTICS INC ( RNAZ ) - CONCURRENT EQUITY INVESTMENT

OF $25

MILLION FROM CK LIFE SCIENCES INTO TRANSCODE

* TRANSCODE THERAPEUTICS INC ( RNAZ ): PHILIPPE CALAIS APPOINTED AS

TRANSCODE'S CHIEF EXECUTIVE OFFICER AND REMAINS CHAIRMAN

* TRANSCODE THERAPEUTICS INC ( RNAZ ): TOM FITZGERALD STEPS DOWN AS

INTERIM

CHIEF EXECUTIVE OFFICER BUT REMAINS CHIEF FINANCIAL OFFICER

Source text:

Further company coverage: